Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05688969 · ClinicalTrials.gov registry record · NA
Mechanisms of Anabolic Osteoporosis Therapy
A NA study of Osteoporosis, Postmenopausal, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05688969 is a NA study of Osteoporosis, Postmenopausal that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 3,258-participant average among 10 other Osteoporosis, Postmenopausal trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05688969, a NA study of Osteoporosis, Postmenopausal, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
Conditions Studied
Interventions
- OTHER early versus late biopsy
Study Locations (1)
Massachusetts
- Mass General Brigham - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-06-14 |
| Est. Completion | 2028-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05688969
The ClinicalTrials.gov registry entry for NCT05688969 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,258-participant average among 10 other Osteoporosis, Postmenopausal trials with a reported enrollment target (100% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 1 intervention - of which early versus late biopsy is the first listed.
NCT05688969 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05688969 about?
NCT05688969 is a clinical study titled "Mechanisms of Anabolic Osteoporosis Therapy". The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
What is the current status of trial NCT05688969?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2023-06-14. Estimated completion is 2028-12.
What conditions does trial NCT05688969 study?
This clinical trial studies the following conditions: Osteoporosis, Postmenopausal.
What interventions are being tested in trial NCT05688969?
The interventions under investigation include: early versus late biopsy (OTHER).
Who is sponsoring clinical trial NCT05688969?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05688969 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis, Postmenopausal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Comparative Efficacy, Safety, PK, and Immunogenicity Study
ACTIVE NOT RECRUITING · Phase 3
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Romosozumab Use to Build Skeletal Integrity
ACTIVE NOT RECRUITING · Phase 4
-
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.